RT Journal Article
SR Electronic
T1 Urine metabolomic profiles of autism and autistic traits – a twin study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.24.23289030
DO 10.1101/2023.04.24.23289030
A1 Arora, Abishek
A1 Mastropasqua, Francesca
A1 Bölte, Sven
A1 Tammimies, Kristiina
YR 2023
UL http://medrxiv.org/content/early/2023/04/24/2023.04.24.23289030.abstract
AB Currently, there are no reliable biomarkers for autism diagnosis. The heterogeneity of autism and several co-occurring conditions are key challenges to establish these. Here, we used untargeted mass spectrometry-based urine metabolomics to investigate metabolic differences for autism diagnosis and autistic traits in a well-characterized twin cohort (N=105). We identified 208 metabolites in the urine samples of the twins. No clear, significant metabolic drivers for autism diagnosis were detected when controlling for other neurodevelopmental conditions. However, we identified nominally significant changes for several metabolites. For instance, phenylpyruvate (p=0.019) and taurine (p=0.032) were elevated in the autism group, while carnitine (p=0.047) was reduced. We furthermore accounted for the shared factors, such as genetics within the twin-pairs, and report additional metabolite differences. Based on the nominally significant metabolites for autism diagnosis, arginine and proline metabolism pathway (p=0.024) was enriched. We also investigated the association between quantitative autistic traits, as measured by the Social Responsiveness Scale 2nd Edition, and metabolite differences, identifying a greater number of nominally significant metabolites and pathways. A significant positive association between indole-3-acetate and autistic traits was observed within twin-pairs (adjusted p=0.031). The utility of urine biomarkers in autism, therefore, remains unclear, with mixed findings from different study populations.Lay Abstract Earlier literature has suggested that there are chemical molecules (metabolites) in the urine samples of autistic individuals that could be linked with their diagnosis of autism. However, there are still mixed results and uncertainty if any of these metabolites could be used as biomarkers (chemical molecules that indicate a biological condition). In this study, we analysed urine samples of 105 twins from Sweden, of which 48 were identical or fraternal twins, and the analysed metabolite levels were compared between those twins diagnosed with autism and those without a diagnosis. Additionally, we tested if the metabolite levels were different in relation to the level of autistic behaviour. The metabolite levels were measured using mass spectrometry, allowing us to identify hundreds of chemical molecules present in a urine sample followed with testing their significance for autism diagnosis or autistic traits. No single metabolite was found to be highly associated with a diagnosis of autism. However, indole-3-acetate, a metabolite produced by the breakdown of the amino acid tryptophan, was associated with the level of autistic behaviour within the twins. Nevertheless, several metabolites showed some association with autism or the level of autistic behaviour, while revealing interesting pathways for studies in the future.Competing Interest StatementA.A., F.M., and K.T. declare no competing interests. S.B. declares no direct conflict of interest related to this article. He discloses that he has in the last three years acted as an author, consultant, or lecturer for Medice and Roche. He receives royalties for textbooks and diagnostic tools from Hogrefe, Kohlhammer, UTB and Liber. S.B. is a partner in NeuroSupportSolutions International AB.Funding StatementThe project was supported by the Swedish Research Council (S.B., and K.T.), Swedish Foundation for Strategic Research (K.T.), the Swedish Brain Foundation – Hjärnfonden (K.T.), the Harald and Greta Jeanssons Foundations (K.T.), Åke Wiberg Foundation (K.T.), Strategic Research Area Neuroscience Stratneuro (K.T.), The Swedish Foundation for International Cooperation in Research and Higher Education STINT (K.T.), and Board of Research at Karolinska Institutet (K.T.). Open access funding provided by Karolinska Institutet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Swedish Ethical Review Authority (2016/1452-31) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe utilised code is available on GitHub (https://github.com/Tammimies-Lab/RATSS-Metabolomics) or available upon request from the corresponding author (kristiina.tammimies{at}ki.se).